This dynamic new report from Medtech Insight includes analyses of products, current/forecast markets, competitors, and opportunities in the U.S. market for pain management products. Product areas covered by the scope of this report include pain management pharmaceuticals (e.g., nonprescription analgesics and anesthetics including systemic and topical formulations, as well as prescription analgesics and anesthetics including prescription NSAIDs, opioid analgesics, opioid/nonopioid combination analgesics, antimigraine analgesics, adjuvant analgesics, and general/regional/local anesthetics) and pain management devices (e.g., electrical stimulators including TENS systems and neurostimulators, as well as analgesia infusion pumps including implantable and external models).
During the forecast period covered by this report, the combined U.S. market for pain management products is projected to increase from $36.4 billion in 2013 to $44.7 billion in the year 2018. Pain management pharmaceuticals account for more than 92% of total sales, with pain management devices accounting for the remaining 8% of sales.
EXECUTIVE SUMMARY i. Pain Management Pharmaceuticals a. Nonprescription Analgesics and Anesthetics i. Nonprescription Systemic Analgesics ii. Nonprescription Topical Analgesics iii. Market Forecast b. Prescription Analgesics and Anesthetics i. Prescription Non-Steroidal Anti-Inflammatory Drugs ii. Opioid Analgesics iii. Opioid/Nonopioid Combination Analgesics iv. Antimigraine Analgesics v. Adjuvant Analgesics vi. General, Regional, and Local Anesthetics vii. Market Forecast c. Combined Market Forecast ii. Pain Management Devices a. Electrical Stimulators i. Transcutaneous Electrical Nerve Stimulators ii. Neurostimulators iii. Market Forecast b. Analgesia Infusion Pumps i. Implantable Analgesia Infusion Pumps ii. External Analgesia Infusion Pumps iii. Market Forecast c. Combined Market Forecast iii. Combined Market Forecast Exhibit ES-1: Nonprescription Analgesics/Anesthetics, Market Share, by Product Segment, 2013 and 2018 Exhibit ES-2: Prescription Analgesics/Anesthetics, Market Share, by Product Segment, 2013 and 2018 Exhibit ES-3: Pain Management Pharmaceuticals, Combined Market Share, by Product Segment, 2013 and 2018 Exhibit ES-4: Electrical Stimulators, Market Share, by Product Segment, 2013 and 2018 Exhibit ES-5: Analgesia Infusion Pumps, Market Share, by Product Segment, 2013 and 2018 Exhibit ES-6: Pain Management Devices, Combined Market Share, by Product Segment, 2013 and 2018 Exhibit ES-7: Pain Management Pharmaceuticals and Devices, Combined Market Share, by Product Segment, 2013 and 2018 1. PAIN MANAGEMENT OVERVIEW 1.1 Pain Physiology 1.1.1 The Nervous System 1.1.2 Pain Perception 1.1.3 Pain Classification 188.8.131.52 Nociceptive Pain 184.108.40.206 Non-Nociceptive Pain 220.127.116.11 Acute Pain 18.104.22.168 Chronic Pain 1.2 Pain Assessment Techniques 1.3 Pain Prevalence 1.4 Common Pain Syndromes 1.4.1 Arthritis Pain 1.4.2 Back Pain 1.4.3 Burn Pain 1.4.4 Cancer Pain 1.4.5 Headache Pain 1.4.6 Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome Pain 1.4.7 Obstetric Pain 1.4.8 Podiatric Pain 1.4.9 Sciatic Pain 1.4.10 Temporomandibular Pain 1.4.11 Trauma Pain 1.5 Clinical Approaches to Pain Management 1.5.1 Pain Management Guidelines 1.5.2 Pain Management Guidelines for Older Adults 1.5.3 Interventional Pain Management Guidelines 1.5.4 Pain Management Options 22.214.171.124 Pharmaceutical Options 126.96.36.199 Device-Based Options 188.8.131.52 Alternative Therapy Options Exhibit 1-1: Common Causes of Neuropathic Pain Exhibit 1-2: United States Population, by Selected Ages, 1990-2050 Exhibit 1-3: Overview of the Joint Commission's Standards for Pain Assessment and Management 2. PAIN MANAGEMENT PHARMACEUTICALS 2.1 Pharmaceutical Formulations and Drug Delivery 2.1.1 Oral Drug Delivery 2.1.2 Injection/Infusion Drug Delivery 184.108.40.206 Injection 220.127.116.11.1 Intramuscular Injection 18.104.22.168.2 Subcutaneous Injection 22.214.171.124 Infusion 126.96.36.199.1 Intravenous Infusion 188.8.131.52.2 Intraspinal Infusion 184.108.40.206.3 Intraoperative Site Infusion 2.1.3 Inhalation Drug Delivery 2.1.4 Transdermal Drug Delivery 2.1.5 Transmucosal Drug Delivery 2.1.6 Nonsteroidal Anti-Inflammatory Drugs 220.127.116.11 Heart Attack and Hypertension Risks 18.104.22.168 The Food and Drug Administration and Labeling 22.214.171.124 Naproxen Risks 2.2 The Benefits of Aspirin 2.2.1 Aspirin and Heart Attack/Stroke Prevention 2.2.2 Aspirin and Heart Failure 2.2.3 Aspirin and Cancer Prevention 2.3 Market Analysis 2.3.1 Nonprescription Analgesics and Anesthetics 126.96.36.199 Market Forecast 188.8.131.52 Nonprescription Systemic Analgesics 184.108.40.206.1 Acetaminophen 220.127.116.11.2 Nonprescription Nonsteroidal Anti-Inflammatory Drugs 18.104.22.168.3 Market Forecast 22.214.171.124.4 Competitive Analysis 126.96.36.199 Nonprescription Topical Analgesics and Anesthetics 188.8.131.52.1 Amino Amides and Esters 184.108.40.206.2 Capsaicin 220.127.116.11.3 Methyl and Trolamine Salicylates 18.104.22.168.4 Topical Patches 22.214.171.124.5 Market Forecast 126.96.36.199.6 Competitive Analysis 2.3.2 Prescription Analgesics and Anesthetics 188.8.131.52 Market Forecast 184.108.40.206 Prescription Nonsteroidal Anti-Inflammatory Drugs 220.127.116.11.1 Acetic Acid Derivatives 18.104.22.168.2 Anthranilic Acid Derivatives 22.214.171.124.3 Cyclooxygenase-2 Selective Inhibitors 126.96.36.199.4 Enolic Acid Derivatives 188.8.131.52.5 Propionic Acid Derivatives 184.108.40.206.6 Salicylic Acid Derivatives 220.127.116.11.7 Market Forecast 18.104.22.168.8 Competitive Analysis 22.214.171.124 Opioid Analgesics 126.96.36.199.1 Buprenorphine 188.8.131.52.2 Butorphanol 184.108.40.206.3 Codeine 220.127.116.11.4 Fentanyl 18.104.22.168.5 Hydromorphone 22.214.171.124.6 Levorphanol 126.96.36.199.7 Meperidine 188.8.131.52.8 Morphine 184.108.40.206.9 Nalbuphine 220.127.116.11.10 Oxycodone 18.104.22.168.11 Oxymorphone 22.214.171.124.12 Pentazocine 126.96.36.199.13 Propoxyphene 188.8.131.52.14 Remifentanil 184.108.40.206.15 Tramadol 220.127.116.11.16 Tapentadol 18.104.22.168.17 Hydrocodone 22.214.171.124.18 Market Forecast 126.96.36.199.19 Competitive Analysis 188.8.131.52 Opioid/Nonopioid Combination Analgesics 184.108.40.206.1 Market Forecast 220.127.116.11.2 Competitive Analysis 18.104.22.168 Antimigraine Analgesics 22.214.171.124.1 Diclofenac 126.96.36.199.2 Dihydroergotamine 188.8.131.52.3 Divalproex Sodium 184.108.40.206.4 Triptans 220.127.116.11.5 Market Forecast 18.104.22.168.6 Competitive Analysis 22.214.171.124 Adjuvant Analgesics 126.96.36.199.1 Anticonvulsants 188.8.131.52.2 Antidepressants 184.108.40.206.3 Corticosteriods 220.127.116.11.4 Market Forecast 18.104.22.168.5 Competitive Analysis 22.214.171.124 General, Regional, and Local Anesthetics 126.96.36.199.1 Inhalation General Anesthetics 188.8.131.52.2 Intravenous General Anesthetics 184.108.40.206.3 Anesthetics Used in Balanced Anesthesia 220.127.116.11.4 Regional/Local Anesthetics 18.104.22.168.5 Market Forecast 22.214.171.124.6 Competitive Analysis 2.3.3 Combined Market Forecast Exhibit 2-1: Advantages and Disadvantages of Common Drug Delivery Methods Exhibit 2-2: 2014, Selected Nonprescription Analgesics and Anesthetics Exhibit 2-3: 2014, Selected Prescription Analgesics and Anesthetics Exhibit 2-4: Nonprescription Analgesics and Anesthetics, Market Forecast 2013-2018 Exhibit 2-5: Nonprescription Systemic Analgesics, Market Forecast, 2013-2018 Exhibit 2-6: 2013, Nonprescription Systemic Analgesics Market, Share by Supplier Exhibit 2-7: Nonprescription Topical Analgesics/Anesthetics, Market Forecast, 2013-2018 Exhibit 2-8: 2013, Nonprescription Topical Analgesics/Anesthetics Market, Share by Supplier Exhibit 2-9: Prescription Analgesics and Anesthetics, Market Forecast, 2013-2018 Exhibit 2-10: Prescription Nonsteroidal Anti-Inflammatory Drugs, Market Forecast, 2013-2018 Exhibit 2-11: 2013, Prescription Nonsteroidal Anti-Inflammatory Drugs Market, Share by Supplier Exhibit 2-12: Prescription Opioid Analgesics, Market Forecast, 2013-2018 Exhibit 2-13: 2013, Prescription Opioid Analgesics Market, Share by Supplier Exhibit 2-14: Prescription Opioid/Nonopioid Combination Analgesics, Market Forecast, 2013-2018 Exhibit 2-15: Prescription Antimigraine Analgesics, Market Forecast, 2013-2018 Exhibit 2-16: 2013, Prescription Antimigraine Analgesics Market, Share by Supplier Exhibit 2-17: Prescription Adjuvant Analgesics, Market Forecast, 2013-2018 Exhibit 2-18: 2013, Prescription Adjuvant Analgesics Market, Share by Supplier Exhibit 2-19: General, Regional, and Local Anesthetics, Market Forecast, 2013-2018 Exhibit 2-20: 2013, General, Regional, and Local Anesthetics Market, Share by Supplier Exhibit 2-21: Pain Management Pharmaceuticals, Combined Market Forecast, 2013-2018 3. PAIN MANAGEMENT DEVICES 3.1 Electrical Stimulators 3.1.1 Transcutaneous Electrical Nerve Stimulators 126.96.36.199 Market Forecast 188.8.131.52 Competitive Analysis 3.1.2 Neurostimulators 184.108.40.206 Occipital Nerve Stimulation 220.127.116.11 Neuromuscular Stimulators 18.104.22.168 Spinal Cord and Peripheral Nerve Stimulators 22.214.171.124 Market Forecast 126.96.36.199 Competitive Analysis 3.2 Analgesia Infusion Pumps 3.2.1 Implantable Analgesia Infusion Pumps 188.8.131.52 Market Forecast 184.108.40.206 Competitive Analysis 3.2.2 External Analgesia Infusion Pumps 220.127.116.11 Nerve Block 18.104.22.168 Patient-Controlled Analgesia Infusion Pumps 22.214.171.124 Products 126.96.36.199 Market Forecast 188.8.131.52 Competitive Analysis 3.3 Combined Market Forecast Exhibit 3-1: Proposed Fourth Step of the World Health Organization Analgesic Ladder Exhibit 3-2: Selected Painful Conditions Appropriate for Electrical Stimulation Therapy Exhibit 3-3: Transcutaneous Electrical Nerve Stimulators, Market Forecast, 2013-2018 Exhibit 3-4: 2013, Transcutaneous Electrical Nerve Stimulators Market, Share by Supplier Exhibit 3-5: Neurostimulators, Market Forecast, 2013-2018 Exhibit 3-6: 2013, Spinal Cord Stimulators Market, Share by Supplier Exhibit 3-7: 2013, Neuromuscular Stimulators Market, Share by Supplier Exhibit 3-8: Implantable Analgesia Infusion Pumps, Market Forecast, 2013-2018 Exhibit 3-9: 2013, Implantable Analgesia Infusion Pumps Market, Share by Supplier Exhibit 3-10: External Analgesia Infusion Pumps, Market Forecast, 2013-2018 Exhibit 3-11: 2013, External Analgesia Infusion Pumps Market, Share by Supplier Exhibit 3-12: Pain Management Devices, Combined Market Forecast, 2013-2018 4. COMPANY PROFILES 4.1 AstraZeneca PLC 4.2 Baxter Healthcare, Inc./Baxter International, Inc. 4.3 Bayer HealthCare AG/Bayer AG 4.4 Boston Scientific Corporation 4.5 CareFusion Corporation 4.6 Chattem, Inc./sanofi-aventis LLC 4.7 DJO Global, Inc. 4.8 Eli Lilly and Company 4.9 Endo Pharmaceutical Holdings, Inc./Endo International PLC 4.10 GlaxoSmithKline PLC 4.11 Hospira, Inc. 4.12 International Rehabilitative Sciences, Inc., d/b/a RS Medical 4.13 Johnson & Johnson 4.14 Medtronic, Inc. 4.15 Pfizer, Inc. 4.16 Purdue Pharma LP 4.17 Teva Pharmaceutical Industries LTD APPENDIX: COMPANY LISTING